Free Trial
NASDAQ:SRDX

Surmodics Q3 2025 Earnings Report

Surmodics logo
$31.10 -1.07 (-3.33%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$31.10 -0.01 (-0.02%)
As of 09/23/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Surmodics EPS Results

Actual EPS
$0.06
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Surmodics Revenue Results

Actual Revenue
$29.57 million
Expected Revenue
$28.04 million
Beat/Miss
Beat by +$1.53 million
YoY Revenue Growth
N/A

Surmodics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Friday, August 8, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Surmodics' Q4 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Surmodics Earnings Headlines

China’s message to Trump
Did China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.tc pixel
What's Next: Surmodics's Earnings Preview
Surmodics (SRDX) Q3 EPS Turns Positive
See More Surmodics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surmodics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surmodics and other key companies, straight to your email.

About Surmodics

Surmodics (NASDAQ:SRDX) (NASDAQ: SRDX) is a medical technology company specializing in surface modification and drug-eluting coating technologies for medical devices and in vitro diagnostic applications. The company’s core expertise lies in polymer-based solutions that enhance device performance, including hydrophilic coatings to improve catheter lubricity and drug-delivery coatings for cardiovascular and peripheral vascular stents. Surmodics also offers proprietary diagnostic assay platforms and automation solutions for clinical laboratories.

Surmodics’ product portfolio is organized around two main segments: medical device and in vitro diagnostics. In the medical device segment, the company provides therapeutic delivery coatings, surface modifiers, and adhesive technologies for customers developing implants, guide wires, and catheters. On the diagnostics side, Surmodics supplies reagents, assay calibrators, and control materials, as well as instrumentation used in immunoassay and molecular diagnostic workflows.

Founded in Eden Prairie, Minnesota, in 1986, Surmodics has expanded its operations to serve a global client base across North America, Europe, and Asia. The company’s research and development efforts focus on advancing biocompatible polymers and next-generation delivery systems, while its manufacturing facilities adhere to international quality standards. Surmodics collaborates with a diverse set of medical device OEMs, contract manufacturers, and diagnostic companies to bring customized surface and assay solutions to market.

Surmodics is led by President and Chief Executive Officer Richard Carlin, who has overseen strategic partnerships and product launches since taking the helm in 2016. The company maintains a governance structure aimed at innovation and regulatory compliance, with a board comprised of directors experienced in medical technology, life sciences, and global business operations. Through ongoing investment in R&D and customer-driven development, Surmodics seeks to address clinical challenges and improve patient outcomes worldwide.

View Surmodics Profile

More Earnings Resources from MarketBeat